Getting down to the heart of the (gray) matter to treat Parkinson's disease

An agent under consideration for use in PET imaging combats neuronal death to relieve Parkinsonian symptoms in animal models, according to a study published on April 2nd in the Journal of Experimental Medicine.

The movement-related symptoms of Parkinson's disease, including muscle rigidity and tremors, are caused by the loss of dopamine-secreting neurons in the brain. Current therapies aim at increasing and maintaining dopamine levels to correct these motor impairments. However, these approaches do not address the underlying neuronal death that initiated the disease.

David Finkelstein, Kevin Barnham, and colleagues at the University of Melbourne find that the PET imaging agent CuII(atsm) reverses the neurotoxicity that destroys dopamine-secreting neurons. Improvements in motor skills and memory were observed after treatment in four unique animal models of Parkinson's disease. The authors suggest this compound functions as a scavenger of peroxynitrite, whose accumulation is known to promote .

These results point to a potential strategy to restore motor and cognitive function in Parkinson's disease patients by reviving rather than solely masking symptoms.

More information: Hung, L.W., et al. 2012. J. Exp. Med. doi:10.1084/jem.20112285

add to favorites email to friend print save as pdf

Related Stories

Research targets brain region affected by Parkinson's

Nov 08, 2011

A team of researchers at The University of Western Ontario has demonstrated that elimination of one of the neurotransmitters in the part of the brain associated with Parkinson's disease may improve brain function without ...

New knowledge on the pharmacology of dopamine stabilizers

Feb 24, 2012

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease – pridopidine or dopamine stabiliser ACR16 – might operate via previously unknown mechanisms of action. Researchers have ...

Recommended for you

Parkinson's disease reverted at a experimental stage

Dec 19, 2014

Mexican scientists demonstrated experimentally, with adult rats, that mobility can be restored in patients with Parkinson's disease, the major degenerative disease of the motor system worldwide. The experiments ...

EU team launches clinical trial of Parkinson's vaccine

Dec 09, 2014

Today the EU-consortium SYMPATH starts recruitment for a Phase I study of a Parkinson's vaccine candidate called AFFITOPE PD03A. This vaccine is one out of a designated pool of promising vaccine candidates based on AFFiRiS' ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.